Growth Factors in the Regulation of Pericellular Proteolysis: A Review

Cancer Research

Volumn 49, Issue 10, 1989, Pages 2533-2553

  Laiho, Marikki ^a   Keski Oja, Jorma ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; PLASMINOGEN ACTIVATOR;

ANGIOGENESIS; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW;

ANIMAL; CELL DIFFERENTIATION; CELL DIVISION; EXTRACELLULAR MATRIX; GLYCOPROTEINS; GROWTH SUBSTANCES; HOMEOSTASIS; HUMAN; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE HYDROLASES; PLASMINOGEN ACTIVATORS; PLASMINOGEN INACTIVATORS; SUPPORT, NON-U.S. GOV'T;

EID: 0024309860     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Review

References (337)

1. Saksela, O., Vaheri, A., Schleuning, W.-D., Mignatti, P., and Barlati, S. Plasminogen activators, activation inhibitors and α2-macroglobulin produced by cultured normal and malignant cells. Int. J. Cancer, 33: 609-616, 1984.
2. Cajot, J.-F., Kruithof, E. K. O., Schleuning, W.-D., Sordat, B., and Bachman, F. Plasminogen activators, plasminogen activator inhibitors and pro-coagulant analyzed in twenty human tumor cell lines. Int. J. Cancer, 38: 719-727,1986.
3. Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 44: 139-266, 1985.
4. + RNA. Proc. Natl. Acad. Sci. USA, 81: 4727-4731, 1984.
5. Belin, D., Vassalli, J.-D., Combepine, C., Godeau, F., Nagamine, Y., Reich, E., Kocher, H. P., and Duvoisin, R. M. Cloning, nucleotide sequencing and expression of cDNAs encoding mouse urokinase-type plasminogen activator. Eur. J. Biochem., 148: 225-232, 1985.
6. Pennica, D., Holmes, W. E., Kohr, W. J., Harkins, R. N., Vehar, G. A., Ward, C. A., Bennett, W. F., Yelverton, E., Seeburg, P. H., Heyneker, H. L., and Goeddel, D. V. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature (Lond.), 301: 214–221, 1983.
7. Wun, T.-C., Ossowski, L., and Reich, E. A proenzyme form of human urokinase. J. Biol. Chem., 257: 7262-7268, 1982.
8. Vassalli, J.-D., Dayer, J.-M., Wohlwend, A., and Belin, D. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J. Exp. Med., 159: 1653-1668, 1984.
9. Andreasen, P. A., Nielsen, L. S., Grondahl-Hansen, J., Skriver, L., Zeuthen, J., Stephens, R. W., and Dano, K. Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody. EMBO J., 3: 51-56, 1984.
10. Eaton, D. L., Scott, R. W., and Baker, J. B. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. J. Biol. Chem., 259: 6241-6247, 1984.
11. Kielberg, V., Andreasen, P. A., Grendahl-Hansen, J., Skriver, L., and Dano, K. Proenzyme to urokinase-type plasminogen activator in the mouse in vivo. FEBS Lett., 182: 441-445, 1985.
12. Blomquist, M. C., Hunt, L. T., and Baker, W. C. Vaccinia virus 19-kilodalton protein: relationship to several mammalian proteins, including two growth factors. Proc. Natl. Acad. Sci. USA, 81: 7363-7367, 1984.
13. Ichinose, A., Fujikawa, K., and Suyama, T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J. Biol. Chem., 261: 3486–3489, 1986.
14. Lijnen, H. R., Zamarron, C., Blaber, M., Winkler, M. E., and Collen, D. Activation of plasminogen by prourokinase. I. Mechanism. J. Biol. Chem., 261: 1253-1258, 1986.
15. Ellis, V., Scully, M. F., and Kakkar, V. V. Plasminogen activation by single-chain urokinase in functional isolation. A kinetic study. J. Biol. Chem., 262: 14998–15003, 1987.
16. Stump, D. C., Thienpont, M., and Collen, D. Urokinase-related proteins in human urine. Isolation and characterization of single-chain urokinase (pro-urokinase) and urokinase-inhibitor complex. J. Biol. Chem., 261: 1267-1273,1986.
17. Stump, D. C., Lijnen, H. R., and Collen, D. Purification and characterization of single-chain urokinase-type plasminogen activator from human cell cultures. J. Biol. Chem., 261: 1274-1278, 1986.
18. Stoppelli, M. P., Corti, A., Soffientini, A., Cassani, G., Blasi, F., and Assoian, R. K. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc. Natl. Acad. Sci. USA, 82: 4939-4943, 1985.
19. Stoppelli, M. P., Tacchetti, C., Cubellis, M. V., Corti, A., Hearing, V. J., Cassani, G., Appella, E., and Blasi, F. Autocrine saturation of pro-urokinase receptors on human A431 cells. Cell, 45: 675-684, 1986.
20. r55,000 form of the human plasminogen activator, urokinase. J. Cell Biol., 100: 86-92, 1985.
21. r 17,500 region of the A chain of urokinase is required for interaction with a specific receptor in A431 cells. Biochim. Biophys. Acta, 885: 301–308, 1986.
22. Del Rosso, M., Dini, G., and Fibbi, G. Receptors for plasminogen activator, urokinase, in normal and Rous sarcoma virus-transformed mouse fibroblasts. Cancer Res., 45: 630-636, 1985.
23. Blasi, F., Stoppelli, M. P., and Cubellis, M. V. The receptor for urokinase plasminogen activator. J. Cell. Biochem., 32: 179-186, 1986.
24. Blasi, F., Vassalli, J.-D., and Dano, K. Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors. J. Cell Biol., 104: 801–804, 1987.
25. r receptor protein for urokinase-type plasminogen activator. Identification in human tumor cell lines and partial purification. J. Biol. Chem., 263: 2358-2363, 1988.
26. Appella, E., Robinson, E. A., Ullrich, S. J., Stoppelli, M. P., Corti, A., Cassani, C., and Blasi, F. The receptor-binding sequence of urokinase. J. Biol. Chem., 262: 4437-4440, 1987.
27. Kirchheimer, J. C., Wojta, J., Christ, G., and Binder, B. R. Proliferation of a human epidermal tumor cell line stimulated by urokinase. FASEB J., 1: 125-128, 1987.
28. Hajjar, K. A., Hamel, N. M., Harpel, P. C., and Nachman, R. L. Binding of tissue plasminogen activator to cultured human endothelial cells. J. Clin. Invest., 80: 1712-1719, 1987.
29. Salonen, E.-M., Saksela, O., Vartio, T., Vaheri, A., Nielsen, L. S., and Zeuthen, J. Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. J. Biol. Chem., 260: 12302-12307, 1985.
30. Mira-y-Lopez, R., Reich, E., and Ossowski, L. Modulation of plasminogen activator in rodent mammary tumors by hormones and other effectors. Cancer Res., 43: 5467–5477, 1983.
31. Saksela, O. Plasminogen activation and regulation of pericellular proteolysis. Biochim. Biophys. Acta, 823: 35-65, 1985.
32. Ranby, M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim. Biophys. Acta, 704: 461-469, 1982.
33. van der Werf, F., Ludbrook, P. A., Bergman, S. R., Tiefenbrunn, A. J., Fox, K. A. A., De Geest, H., Verstraete, M., Collen, D., and Sobel, B. E. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N. Engl. J. Med., 310: 609-613, 1984.
34. Guerci, A. D., Gerstenblith, G., Brinker, J. A., Chandra, N. C., Gottlieb, S. O., Bahr, R. D., Weiss, J. L., Shapiro, E. P., Flaherty, J. T., Bush, D. E., Chew, P. H., Gottlieb, S. H., Haplerin, H. R., Ouyang, P., Walford, G. D., Bell, W. R., Fatterpaker, A. K., Llewellyn, M., Topol, E. J., Healy, B., Siu, C. O., Becker, L. C., and Weisfeldt, M. L. A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. N. Engl. J. Med., 317: 1613–1618, 1987.
35. Pepper, M. S., Vassalli, J.-D., Montesano, R., and Orci, L. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J. Cell Biol., 105: 2535-2541, 1987.
36. Isseroff, R. R., Fusenig, N. E., and Rifkin, D. B. Plasminogen activator in differentiating mouse keratinocytes. J. Invest. Dermatol., 80: 217–222, 1983.
37. Virji, M. A. G., Vassalli, J.-D., Estensen, R. D., and Reich, E. Plasminogen activator of islets of Langerhans: modulation by glucose and correlation with insulin production. Proc. Natl. Acad. Sci. USA, 77: 875–879, 1980.
38. Granelli-Piperno, A., and Reich, E. Plasminogen activators of the pituitary gland: enzyme characterization and hormonal modulation. J. Cell Biol., 97: 1029-1037, 1983.
39. Lyons, R. M., Keski-Oja, J., and Moses, H. L. Proteolytic activation of latent transforming growth factor-β from fibroblast conditioned medium. J. Cell Biol., 106: 1659-1665, 1988.
40. Lyons, R. M., Gentry, L. E., Purchio, A. F., and Moses, H. L. Proteolytic processing and activation of latent transforming growth factor-β. Proc. Natl. Acad. Sci. USA, in press, 1989.
41. Pepinsky, R. B., Sinclair, L. K., Chow, E. P., Mattaliano, R. J., Manganaro, T. F., Donahoe, P. K., and Cate, R. L. Proteolytic processing of Mullerian inhibiting substance produces a transforming growth factor-β-like fragment. J. Biol. Chem., 263: 18961-18964, 1988.
42. Keski-Oja, J., Laiho, M., and Lohi, J. Activation of latent cell-derived transforming growth factor-β by the plasminogen activator urokinase. 28th Annual Meeting, American Society for Cell Biology, San Francisco, CA. J. Cell. Biol., 107 (Part 3): 50a, 1989.
43. Beers, W. H., Strickland, S., and Reich, E. Ovarian plasminogen activator: relationship to ovulation and hormonal regulation. Cell, 6: 387-394, 1975.
44. Beers, W. H. Follicular plasminogen and plasminogen activator and the effect of plasmin on ovarian follicle wall. Cell, 6: 379-386, 1975.
45. Huarte, J., Belin, D., Bosco, D., Sappino, A.-P., and Vassalli, J.-D. Plasminogen activator and mouse spermatozoa: urokinase synthesis in the male genital tract and binding of the enzyme to the sperm cell surface. J. Cell Biol., 104: 1281-1289, 1987.
46. Strickland, S., Reich, E., and Sherman, M. I. Plasminogen activator in early embryogenesis: enzyme production by trophoblast and parietal endoderm. Cell, 9: 231-240, 1976.
47. Ossowski, L., Biegel, D., and Reich, E. Mammary plasminogen activator: correlation with involution, hormonal modulation and comparison between normal and neoplastic tissue. Cell, 16: 929-940, 1979.
48. Reich, E. Activation of plasminogen. A general mechanism for producing localized extracellular proteolysis. In: R. D. Berlin, L. Herrman, I. H. Lepow, and J. M. Tanzer (eds.), Molecular Basis of Biological Degradative Processes, New York: Academic Press, pp. 155-169, 1980.
49. Mullins, D. E., and Rorlich, S. T. The role of proteinases in cellular invasiveness. Biochim. Biophys. Acta, 695: 177-214, 1983.
50. Ossowski, L., Unkeless, J. C., Tobia, A., Quigley, J. P., Rifkin, D. B., and Reich, E. An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. II. Mammalian fibroblast cultures transformed by DNA and RNA tumor viruses. J. Exp. Med., 137: 112-126, 1973.
51. Unkeless, J. C., Tobia, A., Ossowski, L., Quigley, J. P., Rifkin, D. B., and Reich, E. An enzymatic function associated with transformation of fibroblasts by oncogenic viruses. J. Exp. Med., 137: 85-111, 1973.
52. Pollack, R., Risser, R., Conlon, S., and Rifkin, D. Plasminogen activator production accompanies loss of anchorage regulation in transformation of primary rat embryo cells by Simian virus 40. Proc. Natl. Acad. Sci. USA, 71: 4792-4796, 1974.
53. Rijken, D. C., and Collen, D. Purification and characterization of the plasminogen activator secreted by human melanoma cell lines in culture. J. Biol. Chem., 256: 7035-7041, 1981.
54. Wolf, B. A., and Goldberg, A. R. Lack of correlation between tumorigenicity and level of plasminogen activator in fibroblasts transformed by Rous sarcoma virus. Proc. Natl. Acad. Sci. USA, 75: 4967-4971, 1978.
55. Laug, W. E., Jones, P. A., and Benedict, W. F. Relationships between fibrinolysis of cultured cells and malignancy. J. Natl. Cancer Inst., 54: 173-179, 1975.
56. Sisskin, E. E., Weinstein, I. B., Evans, C. H., and DiPaolo, J. A. Plasminogen activator synthesis accompanying chemical carcinogen induced in vitro transformation of Syrian hamster and guinea-pig fetal cells. Int. J. Cancer, 26: 331-335, 1980.
57. Skriver, L., Larsson, L.-I., Kielberg, V., Nielsen, L. S., Andresen, P. B., Kristensen, P., and Dano, K. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J. Cell Biol., 99: 752-757, 1984.
58. Quigley, J. P. Phorbol ester-induced morphological changes in transformed chick fibroblasts: evidence for direct catalytic involvement of plasminogen activator. Cell, 17: 131-141, 1979.
59. Quigley, J. P., Goldfarb, R. H., Scheiner, C., O’Donnel-Tormey, J., and Yeo, T. K. Plasminogen activator and the membrane of transformed cells. Prog. Clin. Biol. Res., 41: 773-795, 1980.
60. Sullivan, L. M., and Quigley, J. P. An anticatalytic monoclonal antibody to avian plasminogen activator its effect on behavior of RSV-transformed chick fibroblasts. Cell, 45: 905-915, 1986.
61. Ossowski, L., and Reich, E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell, 35: 611-619, 1983.
62. Ossowski, L. Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell, 52: 321-328, 1988.
63. Hearing, V. J., Law, L. W., Corti, A., Appella, E., and Blasi, F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res., 48: 1270–1278, 1988.
64. Pollanen, J., Saksela, O., Salonen, E.-M., Andreasen, P. A., Nielsen, L. S., Dano, K., and Vaheri, A. Distinct localizations of urokinase-type plasminogen activator and its type-1 inhibitor under cultured human fibroblasts and sarcoma cells. J. Cell Biol., 104: 1085-1096, 1987.
65. Pollanen, J., Hedman, K., Nielsen, L. S., Dano, K., and Vaheri, A. Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contact. J. Cell Biol., 106: 87-95, 1988.
66. Plow, E. F., Freaney, D. E., Plescia, J., and Miles, L. A. The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type. J. Cell Biol., 103: 2411-2420, 1986.
67. Fairbairn, S., Gilbert, R., Ojakian, G., Schwimmer, R., and Quigley, J. P. The extracellular matrix of normal chick embryo fibroblasts: its effect on transformed chick fibroblasts and its proteolytic degradation by the trans-formants. J. Cell Biol., 101: 1790-1798, 1985.
68. Salonen, E.-M., Zitting, A., and Vaheri, A. Laminin interacts with plasminogen and its tissue-type activator. FEBS Lett., 172: 29-32, 1984.
69. Knudsen, B. S., Silverstein, R. L., Leung, L. L. K., Harpel, P. C., and Nachman, R. L. Binding of plasminogen to extracellular matrix. J. Biol. Chem., 261: 10765-10771, 1986.
70. Ossowski, L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase. J. Cell Biol., 107: 2437-2447,1988.
71. Travis, J., and Salvesen, G. S. Human plasma proteinase inhibitors. Annu. Rev. Biochem., 52: 655-709, 1983.
72. Granelli-Pipemo, A., and Reich, E. A study of proteases and protease-inhibitor complexes in biological fluids. J. Exp. Med., 146: 223-234, 1978.
73. 1-antitrypsin and the serpins: variation and countervariation. Trends Biochem. Sci., 10: 20-24, 1985.
74. Hill, R. E., and Hastie, N. D. Accelerated evolution in the reactive centre regions of serine protease inhibitors. Nature (Lond.), 326: 96-99, 1987.
75. Sprengers, E. D., and Kluft, C. Plasminogen activator inhibitors. Blood, 69: 381–387, 1987.
76. Knauer, D. J., and Cunningham, D. D. Protease nexins: cell-secreted proteins which regulate extracellular serine proteinases. Trends Biochem. Sci., 9: 231-233, 1984.
77. Phillips, M., Juul, A.-G., and Thorsen, S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim. Biophys. Acta, 802: 99-110, 1984.
78. Sprengers, E. D., Verheijen, J. H., van Hinsbergh, V. W. M., and Emeis, J. J. Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium. Biochim. Biophys. Acta, 801: 163-170,1984.
79. Loskutoff, D. J., and Edgington, T. S. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc. Natl. Acad. Sci. USA, 74: 3903-3907,1977.
80. Loskutoff, D. J., van Mourik, J. A., Erickson, L. A., and Lawrence, D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc. Natl. Acad. Sci. USA, 80: 2956-2960, 1983.
81. Levin, E. G. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc. Natl. Acad. Sci. USA, 80: 6804-6808, 1983.
82. van Mourik, J. A., Lawrence, D. A., and Loskutoff, D. J. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J. Biol. Chem., 259: 14914-14921, 1984.
83. Laug, W. E. Vascular smooth muscle cells inhibit plasminogen activators secreted by endothelial cells. Thromb. Haemostasis, 53: 165-170, 1985.
84. Ny, T., Bjersing, L., Hsueh, A. J. W., and Loskutoff, D. J. Cultured granulosa cells produce two plasminogen activators and an antiactivator, each regulated differently by gonadotropins. Endocrinology, 116: 1666-1668,1985.
85. Cwikel, B. J., Barouski-Miller, P. A., Coleman, P. L., and Gelehrter, T. Dexamethasone induction of an inhibitor of plasminogen activator in HTC hepatoma cells. J. Biol. Chem., 259: 6847-6851, 1984.
86. Coleman, P. L., Patel, P. D., Cwikel, B. J., Rafferty, U. M., Sznycer-Laszuk, R., and Gelehrter, T. D. Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J. Biol. Chem., 261: 4352-4357, 1986.
87. Andreasen, P. A., Nielsen, L. S., Kristensen, P., Grondahl-Hansen, J., Skriver, L., and Dano, K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J. Biol. Chem., 261: 7644-7651, 1986.
88. Kluft, C., Jie, A. F. H., Sprengers, E. D., and Verheijen, J. H. Identification of a reversible inhibitor of plasminogen activators in blood plasma. FEBS Lett., 190: 315-318, 1985.
89. Erickson, L. A., Ginsberg, M. H., and Loskutoff, D. J. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J. Clin. Invest., 74: 1465-1472, 1984.
90. Ny, T., Sawdey, M., Lawrence, D., Millan, J. L., and Loskutoff, D. J. Cloning and sequence of a cDNA coding for the human β-migrating endothelial-cell-type plasminogen activator inhibitor. Proc. Natl. Acad. Sci. USA, 83: 6776-6780, 1986.
91. Pannekoek, H., Veerman, H., Lambers, H., Diergaarde, P., Verweij, C. L., van Zonneweld, A.-J., and van Mourik, J. A. Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J., 5: 2539-2544, 1986.
92. Ginsburg, D., Zehab, R., Yang, A. Y., Rafferty, U. M., Andreasen, P. A., Nielsen, L. S., Dano, K., Lebo, R. V., and Gelehrter, T. D. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J. Clin. Invest., 78: 1673-1680, 1986.
93. Andreasen, P. A., Riccio, A., Welinder, K. G., Douglas, R., Sartorio, R., Nielsen, L. S., Oppenheimer, C., Blasi, F., and Dano, K. Plasminogen activator inhibitor type-1: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett., 209: 213–218, 1986.
94. Bosma, P. J., van der Berg, E. A., Kooistra, T., Siemeniak, D. R., and Slightom, J. L. Human plasminogen activator inhibitor-1 gene. Promoter and structural gene nucleotide sequence. J. Biol. Chem., 263: 9129–9141, 1988.
95. Hekman, C. M., and Loskutoff, D. J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J. Biol. Chem., 260: 11581-11587, 1985.
96. Sprengers, E. D., van Hinsberg, V. W. M., and Jansen, B. G. The active and inactive plasminogen activator inhibitor from human endothelial cell conditioned medium are immunologically and functionally related to each other. Biochim. Biophys. Acta, 883: 233-241, 1986.
97. Levin, E. G. Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells. Blood, 67: 1309-1313,1986.
98. Levin, E. G., and Santell, L. Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells. Blood, 70: 1090–1098, 1987.
99. Erickson, L. A., Hekman, C. M., and Loskutoff, D. J. The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc. Natl. Acad. Sci. USA, 82: 8710-8714, 1986.
100. Kooistra, T., Sprengers, E. D., and van Hinsberg, V. W. M. Rapid inactivation of the plasminogen-activator inhibitor upon secretion from cultured human endothelial cells. Biochem. J., 239: 497-503, 1986.
101. Lambers, J. W. J., Cammenga, M., Konig, B. W., Mertens, K., Pannekoek, H., and van Mourik, J. A. Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids. J. Biol. Chem., 262: 17492-17496, 1987.
102. Nielsen, L. S., Andreasen, P. A., Grondahl-Hansen, J., Skriver, L., and Dano, K. Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass. FEBS Lett., 196: 269-273, 1986.
103. Gelehrter, T. D., and Sznycer-Laszuk, R. Thrombin induction of plasminogen activator-inhibitor in cultured endothelial cells. J. Clin. Invest., 77: 165-169,1986.
104. Crutchley, D. J., and Conanan, L. B. Endotoxin induction of an inhibitor of plasminogen activator in bovine pulmonary artery endothelial cells. J. Biol. Chem., 261: 154-159, 1986.
105. Emeis, J. J., and Kooistra, T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. J. Exp. Med., 163: 1260-1266, 1986.
106. Kawano, T., Morimoto, K., and Uemura, Y. Urokinase inhibitor in human placenta. Nature (Lond.), 217: 253-254, 1968.
107. Astedt, B., Lecander, I., Brodin, T., Lundblad, A., and Low, K. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb. Haemostasis, 55: 122-125, 1985.
108. Hibino, T., Izaki, S., Ohkuma, M., Kon, S., Thorsen, S., and Astedt, B. Epidermal plasminogen activator inhibitor (PAI) is immunologically identical to placental-type PAI-2. FEBS Lett, 231: 202-206, 1988.
109. Golder, J. P., and Stephens, R. W. Minactivin: a human monocyte product which specifically inactivates urokinase-type plasminogen activators. Eur. J. Biochem., 136: 517-522, 1983.
110. Saksela, O., Hovi, T., and Vaheri, A. Urokinase-type plasminogen activator and its inhibitor secreted by cultured human monocyte-macrophages. J. Cell. Physiol., 122: 125-132,1985.
111. Kruithof, E. K. O., Vassalli, J.-D., Schleuning, W.-D., Mattaliano, R. J., and Bachman, F. Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J. Biol. Chem., 261: 11207-11213, 1986.
112. Kiso, U., Kaudewitz, H., Henschen, A., Astedt, B., Kruithof, E. K. O., and Bachmann, F. Determination of intermediates, products and cleavage site in the reaction between plasminogen activator inhibitor type-2 and uroki-nases. FEBS Lett., 230: 51-56, 1988.
113. Ye, R. D., Wun, T.-C., and Sadler, J. E. cDNA cloning and expression in Escherichia coli of a plasminogen activator inhibitor from human placenta. J. Biol. Chem., 262: 3718-3725, 1987.
114. Schleuning, W.-D., Medcalf, R. L., Hession, C., Rothenbuhler, R., Shaw, A., and Kruithof, E. K. O. Plasminogen activator inhibitor 2: Regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells. Mol. Cell. Biol., 7: 4564-4567, 1987.
115. Antalis, T. M., Clark, M. A., Barnes, T., Lehrbach, P. R., Devine, P. L., Schezov, G., Goss, N. H., Stephens, R. W., and Tolstoshev, P. Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor. Proc. Natl. Acad. Sci. USA, 85: 985-989, 1988.
116. Wohlwend, A., Belin, D., and Vassalli, J.-D. Plasminogen activator-specific inhibitors in mouse macrophages: in vivo and in vitro modulation of their synthesis and secretion. J. Immunol., 139: 1278-1284, 1987.
117. Stephens, R. W., Golder, J. P., Fayle, D. R. H., Hume, D. A., Hapel, A. J., Allan, W., Fordham, C. J., and Doe, W. F. Minactivin expression in human monocyte and macrophage populations. Blood, 66: 333-337,1985.
118. Schwartz, B. S., Monroe, M. C., and Levin, E. G. Increased release of plasminogen activator inhibitor type 2 accompanies the human mononuclear cell tissue factor response to lipopolysaccharide. Blood, 71: 734-741, 1988.
119. Scott, R. W., and Baker, J. B. Purification of human protease nexin. J. Biol. Chem., 258: 10439-10444, 1983.
120. Scott, R. W., Bergman, B. L., Bajpai, A., Hersh, R. T., Rodriquez, H., Jones, B. N., Barreda, C., Watts, S., and Baker, J. B. Protease nexin. Properties and a modified purification procedure. J. Biol. Chem., 260: 7029-7034, 1985.
121. Van Nostrand, W. E., and Cunningham, D. D. Purification of protease nexin II from human fibroblasts. J. Biol. Chem., 262: 8508-8514, 1987.
122. Baker, J. B., Low, D. A., Simmer, R. L., and Cunningham, D. D. Protease nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell, 21: 37-45, 1980.
123. Bergman, B. L., Scott, R. W., Bajpai, A., Watts, S., and Baker, J. B. Inhibition of tumor-cell-mediated extracellular matrix destruction by a fibroblast proteinase inhibitor, protease nexin I. Proc. Natl. Acad. Sci. USA, 83: 996-1000, 1986.
124. Farrell, D. H., Wagner, S. L., Yuan, R. H., and Cunningham, D. D. Localization of protease nexin-1 on the fibroblast extracellular matrix. J. Cell. Physiol., 134: 179-188, 1988.
125. Gronke, R. S., Bergman, B. L., and Baker, J. B. Thrombin interaction with platelets. Influence of a platelet protease nexin. J. Biol. Chem., 262: 3030-3036, 1987.
126. Juhan-Vague, I., Moerman, B., De Cock, F., Aillaud, M. F., and Collen, D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb. Res., 33: 523-530,1984.
127. Kruithof, E. K. O., Gudinchet, A., and Bachmann, F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Blood, 59: 7-12, 1988.
128. Paramo, J. A., Alfaro, M. J., and Rocha, E. Postoperative changes in the plasmatic levels of tissue-type plasminogen activator and its fast-acting inhibitor-relationship to deep vein thrombosis and influence of prophylaxis. Thromb. Haemostasis, 54: 713-716, 1985.
129. Kruithof, E. K. O., Nicolosa, G., and Bachmann, F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood, 70: 1645-1653, 1987.
130. Pledger, W. J., Stiles, C. D., Antoniades, H. N., and Scher, C. D. An ordered sequence of events is required before BALB/c-3T3 cells become committed to DNA synthesis. Proc. Natl. Acad. Sci. USA, 75: 2839-2843, 1978.
131. Barnes, D., and Sato, G. Serum-free cell culture: a unifying approach. Cell, 22: 649-655, 1980.
132. Bottenstein, J. E. Defined media and studies of growth factors. In: G. Guroff (ed.), Growth and Maturation Factors, New York: John Wiley & Sons, Inc., Vol. 1, pp. 249-266,1983.
133. Wharton, W., Leof, E., Olashaw, N., O’Keefe, E. J., and Pledger, W. J. Mitogenic response to epidermal growth factor (EGF) modulated by platelet-derived growth factor in cultured fibroblasts. Exp. Cell Res., 147: 443-448, 1983.
134. 1progression in competent BALB/c-3T3 cells. Exp. Cell Res., 141: 107-115,1982.
135. Holley, R. W. Control of growth of mammalian cells in cell culture. Nature (Lond.), 258: 487-490, 1975.
136. Carpenter, G., and Zendegui, J. G. Epidermal growth factor, its receptor, and related proteins. Exp. Cell Res., 164: 1-10, 1986.
137. Downward, J., Yarden, Y., Mayes, E., Scrace, G. T., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., and Waterfield, M. D. Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature (Lond.), 307: 521-527, 1984.
138. Ullrich, A., Coussens, L., Hayflick, J. S., Dull, T. J., Gray, A., Tam, A. W., Lee, J., Yarden, Y., Libermann, T. A., Schlessinger, J., Downward, J., Mayes, E. L. V., Whittle, N., Waterfield, M. D., and Seeburg, P. H. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amphified gene in A431 epidermoid carcinoma cells. Nature (Lond.), 309: 418-425, 1984.
139. Marquardt, H., and Todaro, G. J. Human transforming growth factor. Production by a melanoma cell line, purification, and initial characterization. J. Biol. Chem., 257: 5220-5225, 1982.
140. Derynck, R., Roberts, A. B., Winkler, M. E., Chen, E. Y., and Goeddel, D. V. Human transforming growth factor-α: precursor structure and expression in E. coli. Cell, 38: 287-297, 1984.
141. Eppstein, D. A., Marsh, Y. V., Schreiber, A. B., Newman, S. R., Todaro, G. J., and Nestor, J. J., Jr. Epidermal growth factor receptor occupancy inhibits vaccinia virus infection. Nature (Lond.), 318: 663-665, 1985.
142. Chang, W., Upton, C., Hu, S.-L., Purchio, A. F., and McFadden, G. The genome of Shope fibroma virus, a tumorigenic poxvirus, contains a growth factor gene sequence similarity to those encoding epidermal growth factor and transforming growth factor a. Mol. Cell. Biol., 7: 535-540, 1987.
143. Upton, C., Macen, J. L., and McFadden, G. Mapping and sequencing of a gene from myxoma virus that is related to those encoding epidermal growth factor and transforming growth factor a. J. Virol., 61: 1271–1275, 1987.
144. DeLarco, J. E., and Todaro, G. J. Sarcoma growth factor (SGF): specific binding to epidermal growth factor (EGF) membrane receptors. J. Cell. Physiol., 102: 267-277, 1980.
145. Reynolds, F. H., Jr., Todaro, G. J., Fryling, C., and Stephenson, J. R. Human transforming growth factors induce tyrosine phosphorylation of EGF receptors. Nature (Lond.), 292: 259-262, 1981.
146. Massague, J. Epidermal growth factor-like transforming growth factor. II. Interaction with epidermal growth factor receptors in human placenta membranes and A431 cells. J. Biol. Chem., 258: 13614–13620, 1983.
147. Twardzik, D. R., Ranchalis, J. E., and Todaro, G. J. Mouse embryonic transforming growth factors related to those isolated from tumor cells. Cancer Res., 42: 590-593, 1982.
148. Twardzik, D. R. Differential expression of transforming growth factor-α during prenatal development of the mouse. Cancer Res., 45: 5413–5416, 1985.
149. Derynck, R., Goeddel, D. V., Ullrich, A., Gutterman, J. U., Williams, R. D., Bringman, T. S., and Berger, W. H. Synthesis of messenger RNAs for transforming growth factors α and β and the epidermal growth factor receptor by human tumors. Cancer Res., 47: 707-712, 1987.
150. Coffey, R. J., Jr., Derynck, R., Wilcox, J. N., Bringman, T. S., Goustin, A. S., Moses, H. L., and Pittelkow, M. R. Production and autoinduction of transforming growth factor-α in human keratinocytes. Nature (Lond.), 328: 817-820,1987.
151. Ibbotson, K. J., D’Souza, S. M., Ng, K. W., Osborne, C. K., Niall, M., Martin, T. J., and Mundy, G. R. Tumor-derived growth factor increases bone resorption in a tumor associated with humoral hypercalcemia of malignancy. Science (Wash. DC), 221: 1292-1294, 1983.
152. Ibbotson, K. J., Twardzik, D. R., D’Souza, S. M., Hargreaves, W. R., Todaro, G. J., and Mundy, G. R. Stimulation of bone resorption in vitro by synthetic transforming growth factor-α. Science (Wash. DC), 228: 1007-1009,1985.
153. Schreiber, A. B., Winkler, M. E., and Derynck, R. Transforming growth factor-α: a more potent angiogenic mediator than epidermal growth factor. Science (Wash. DC), 232: 1250-1253, 1986.
154. Schultz, G. S., White, M., Mitchell, R., Brown, G., Lynch, J., Twardzik, D. R., and Todaro, G. J. Epithelial wound healing enhanced by transforming growth factor-α and vaccinia growth factor. Science (Wash. DC), 235: 350-352, 1987.
155. Gospodarowicz, D., Ferrara, N., Schweigerer, L., and Neufeld, G. Structural characterization and biological functions of fibroblast growth factor. Endocr. Rev., 8: 95-114, 1987.
156. Unsicker, K., Reichert-Preibsch, H., Schmidt, R., Pettmann, B., Labourdette, G., and Sensenbrenner, M. Astroglial and fibroblast growth factors have neurotrophic functions for cultured peripheral and central nervous system neurons. Proc. Natl. Acad. Sci. USA, 84: 5459-5463, 1987.
157. Pettmann, B., Weibel, M., Sensenbrenner, M., and Labourdette, G. Purification of two astroglial growth factors from bovine brain. FEBS Lett., 189: 102-108,1985.
158. Taira, M., Yoshida, T., Miyagawa, K., Sakamoto, H., Terada, M., and Sugimura, T. cDNA sequence of human transforming gene hst and identification of the coding sequence required for transforming activity. Proc. Natl. Acad. Sci. USA, 84: 2980-2984, 1987.
159. Delli Bovi, P., Curatola, A., Kern, F.G., Greco, A., Ittman, M., and Basilico, C. An oncogene isolated by transfection of Kaposi sarcoma DNA encodes a growth factor that is member of the FGF family. Cell, 50: 729-737, 1987.
160. O’Garra, A., Umland, S., De France, T., and Christiansen, J. “B-cell factors” are pleiotropic. Immunol. Today, 9: 45-54, 1988.
161. Tosato, G., Seamon, K. B., Goldman, N. D., Sehgal, P. B., May, L. T., Washington, G. C., Jones, K. D., and Pike, S. E. Monocyte-derived human B-cell growth factor identified as interferon-β2 (BSF-2, IL-6). Science (Wash. DC), 239: 502-504, 1988.
162. Postlethwaite, A. E., Raghow, R., Stricklin, G. P., Poppleton, H., Seyer, J. M., and Kang, A. H. Modulation of fibroblast functions by interleukin 1: increased steady-state accumulation of type 1 procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 α and β. J. Cell Biol., 106: 311-318, 1988.
163. Whetton, A. D., and Dexter, T. M. Haemopoietic growth factors. Trends Biochem. Sci., 11: 207-211, 1986.
164. Nicola, N. A. Hemopoietic growth factors and their interactions with specific receptors. J. Cell. Physiol. Suppl., 5: 9-14, 1987.
165. Roberts, R., Gallagher, J., Spooncer, E., Allen, T. D., Bloomfield, F., and Dexter, T. M. Heparan sulfate bound growth factors: a mechanism for stromal cell mediated haemopoiesis. Nature (Lond.), 332: 376-378, 1988.
166. Sherr, C. J., Rettenmeier, C. W., Sacca, R., Roussel, M. F., Look, A. T., and Stanley, E. R. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor. Cell, 41: 665–676, 1985.
167. Roussel, M. F., Dull, T. J., Rettenmier, C. W., Ralph, P., Ullrich, A., and Sherr, C. J. Transforming potential of the c-fms proto-oncogene (CSF-1 receptor). Nature (Lond.), 325: 549-552, 1987.
168. Griffin, J. D., Rambaldi, A., Vellenga, E., Young, D. C., Ostapovicz, D., and Cannistra, S. A. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulating factors. Blood, 70: 1218-1221, 1987.
169. Paucker, K., Cantell, K., and Henle, W. Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells. Virology, 17: 324-334, 1962.
170. Jonak, G. J., and Knight, E. Selective induction of c-myc mRNA in Daudi cells by human β-interferon. Proc. Natl. Acad. Sci. USA, 81: 1747–1750, 1984.
171. Tominaga, S., and Lengyel, P. β-interferon alters the pattern of proteins secreted from quiescent and platelet-derived growth factor-treated BALB/c-3T3 cells. J. Biol. Chem., 260: 1975-1978, 1985.
172. Zullo, J. N., Cochran, B. H., Huang, A. S., and Stiles, C. D. Platelet-derived growth factor and double-stranded ribonucleic acids stimulate the expression of the same genes in 3T3 cells. Cell, 43: 793-800, 1985.
173. Beutler, B., and Cerami, A. Cachectin: more than a tumor necrosis factor. N. Engl. J. Med., 316: 379–385, 1987.
174. Vilcek, J., Tsujimoto, M., Palombella, V. J., Kohase, M., and Le, J. Tumor necrosis factor receptor binding and mitogenic action in fibroblasts. J. Cell. Physiol. Suppl., 5: 57-61, 1987.
175. 2-interferon by tumor necrosis factor: a homeostasis mechanism in the control of cell proliferation. Cell, 45: 659-666, 1986.
176. Vilcek, J., Palombella, V. J., Henriksen-DeStefano, D., Swenson, C., Fein-man, R., Hirai, M., and Tsujimoto, M. Fibroblast growth-enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors. J. Exp. Med., 163: 632-643, 1986.
177. Goustin, A. S., Leof, E. B., Shipley, G. D., and Moses, H. L. Growth factors and cancer. Cancer Res., 46: 1015-1029, 1986.
178. Todaro, G. J., De Larco, J. E., and Cohen, S. Transformation by murine and feline sarcoma viruses specifically blocks binding of epidermal growth factor to cells. Nature (Lond.), 264: 26-31, 1976.
179. Todaro, G. J., and De Larco, J. E. Growth factors produced by sarcoma virus-transformed cells. Cancer Res., 38: 4147-4154, 1978.
180. De Larco, J. E., and Todaro, G. J. Growth factors from murine sarcoma virus-transformed cells. Proc. Natl. Acad. Sci. USA, 75: 4001-4005, 1978.
181. Sporn, M. B., and Todaro, G. J. Autocrine secretion and malignant transformation of cells. N. Engl. J. Med., 303: 878-880, 1980.
182. Coffey, R. J., Jr., Goustin, A. S., Soderquist, A. M., Shipley, G. D., Wolfshohl, J., Carpenter, G., and Moses, H. L. Transforming growth factor a and β expression in human colon cancer lines: implications for an autocrine model. Cancer Res., 47: 4590-4594, 1987.
183. Watanabe, S., Lazar, E., and Sporn, M. B. Transformation of normal rat kidney (NRK) cells by an infectious retrovirus carrying a synthetic rat type a transforming growth factor gene. Proc. Natl. Acad. Sci. USA, 84: 1258-1262, 1987.
184. Kaplan, P. L., and Ozanne, B. Cellular responsiveness to growth factors correlates with a cell’s ability to express the transformed phenotype. Cell, 33: 931-938, 1983.
185. Newman, M. J., Lane, E. A., Nugent, M. A., and Racker, E. Induction of anchorage-independent growth by epidermal growth factor and altered sensitivity to type β transforming growth factor in partially transformed rat kidney cells. Cancer Res., 46: 5842-5850, 1986.
186. Lee, L.-S., and Weinstein, I. B. Epidermal growth factor, like phorbol esters, induces plasminogen activator in HeLa cells. Nature (Lond.), 274: 696-697,1978.
187. Eaton, D. L., and Baker, J. B. Phorbol esters and mitogens stimulate human fibroblast secretions of plasmin-activatable plasminogen activator and protease nexin, an antiactivator/antiplasmin. J. Cell Biol., 97: 323-328, 1983.
188. Jetten, A. M., and Goldfarb, R. H. Action of epidermal growth factor and retinoids on anchorage-dependent and -independent growth of non-trans-formed rat kidney cells. Cancer Res., 43: 2094-2099, 1983.
189. Hamilton, J. A., Lingelbach, S., Partridge, N. C., and Martin, T. J. Stimulation of plasminogen activator in osteoblast-like cells by bone-resorbing hormones. Biochem. Biophys. Res. Commun., 122: 230-236, 1984.
190. Stoppelli, M. P., Verde, P., Grimaldi, G., Locatelli, E. K., and Blasi, F. Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor-promoter phorbol myristate acetate. J. Cell Biol., 102: 1235-1244, 1986.
191. Laiho, M., Saksela, O., Andreasen, P. A., and Keski-Oja, J. Enhanced production and extracellular deposition of the endothelial-type plasminogen activator inhibitor in cultured human lung fibroblasts by transforming growth factor-β. J. Cell Biol., 103: 2403-2410, 1986.
192. Montesano, R., Vassalli, J.-D., Baird, A., Guillemin, R., and Orci, L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc. Natl. Acad. Sci. USA, 83: 7297-7301,1986.
193. Moscatelli, D., Presta, M., and Rifkin, D. B. Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis and migration. Proc. Natl. Acad. Sci. USA, 83: 2091-2095, 1986.
194. Presta, M., Moscatelli, D., Joseph-Silverstein, J., and Rifkin, D. B. Purification from a hepatoma cell line a basic fibroblast growth factor-like molecule which stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol. Cell. Biol., 6: 4060-4066, 1986.
195. Laiho, M., Saksela, O., and Keski-Oja, J. Transforming growth factor-β induction of type-1 plasminogen activator inhibitor. Pericellular deposition and sensitivity to exogenous urokinase. J. Biol. Chem., 262: 17467-17474, 1987.
196. Lucore, C. L., Fujii, S., Wun, T.-C., Sobel, B. E., and Billadello, J. J. Regulation of expression of type 1 plasminogen activator inhibitor in Hep G2 cells by epidermal growth factor. J. Biol. Chem., 263: 15845–15848, 1988.
197. Saksela, O., Moscatelli, D., and Rifkin, D. B. The opposing effects of basic fibroblast growth factor and transforming growth factor-β on the regulation of plasminogen activator activity in capillary endothelial cells. J. Cell Biol., 105: 957-963, 1987.
198. Lin, H.-S., and Gordon, S. Secretion of plasminogen activator by bone marrow-derived mononuclear phagocytes and its enhancement by colony-stimulating factors. J. Exp. Med., 150: 231-245, 1979.
199. Hume, D. A., and Gordon, S. The correlation between plasminogen activator activity and thymidine incorporation in mouse bone marrow-derived macrophages. Exp. Cell Res., 150: 347-355, 1984.
200. Hovi, T., Saksela, O., and Vaheri, A. Increased secretion of plasminogen activator by human macrophages after exposure to leucocyte interferon. FEBS Lett., 129: 233-236, 1981.
201. Collart, M. A., Belin, D., Vassalli, J.-D., De Kossodo, S., and Vassalli, P. γ-Interferon enhances macrophage transcription of the tumor necrosis fac-tor/cachectin, interleukin-1 and urokinase genes, which are controlled by short-lived repressors. J. Exp. Med., 164: 2113-2118, 1986.
202. Schleef, R. R., Bevilacqua, M. P., Sawdey, M., Gimbrone, M. A., and Loskutoff, D. J. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J. Biol. Chem., 263: 5797-5803, 1988.
203. Nachman, R. L., Hajjar, K. A., Silverstein, R. L., and Dinarello, C. A. Interleukin 1 induces endothelial cell synthesis of plasminogen activator inhibitor. J. Exp. Med., 163: 1595-1600, 1986.
204. Gramse, M., Breviario, F., Pintucci, G., Millet, I., Dejana, E., van Damme, J., Donati, M. B., and Mussoni, L. Enhancement by interleukin-1 (IL-1) of plasminogen activator inhibitor (PA-I) activity in cultured human endothelial cells. Biochem. Biophys. Res. Commun., 139: 720-727, 1986.
205. Assoian, R. K., and Sporn, M. B. Type β transforming growth factor in human platelets: release during platelet degranulation and action on vascular smooth muscle cells. J. Cell Biol., 102: 1217-1223, 1986.
206. Stern, D. M., Bank, I., Nawroth, P. P., Cassimeris, J., Kisel, W., Fenton, J. W., Dinarello, C., Chess, L., and Jaffe, E. A. Self-regulation of procoag-ulant events on the endothelial cell surface. J. Exp. Med., 162: 1223-1235, 1985.
207. Sporn, M. B., Roberts, A. B., Wakefield, L. M., and de Combrugghe, B. Some recent advances in the chemistry and biology of transforming growth factor-β. J. Cell Biol., 105: 1039-1045, 1987.
208. Childs, C. B., Proper, J. A., Tucker, R. F., and Moses, H. L. Serum contains a platelet-derived transforming growth factor. Proc. Natl. Acad. Sci. USA, 79: 5312-5316, 1982.
209. Assoian, R. K., Komoriya, A., Meyers, C. A., Miller, D. M., and Sporn, M. B. Transforming growth factor-β in human platelets. Identification of a major storage site, purification, and characterization. J. Biol. Chem., 258: 7155-7160,1983.
210. Seyedin, S. M., Thomas, T. C., Thompson, A. Y., Rosen, D. M., and Piez, K. A. Purification and characterization of two cartilage-inducing factors from bovine demineralized bone. Proc. Natl. Acad. Sci. USA, 82: 2267-2271,1985.
211. Seyedin, S. M., Thompson, A. Y., Bentz, H., Rosen, D. M., McPherson, J. M., Conti, A., Siegel, N. R., Galluppi, G. R., and Piez, K. A. Cartilage-inducing factor-A: apparent identity to transforming growth factor-β. J. Biol. Chem., 261: 5693-5695, 1986.
212. Derynck, R., Jarrett, J. A., Chen, E. Y., Eaton, D. H., Bell, J. R., Assoian, R. K., Roberts, A. B., Sporn, M. B., and Goeddel, D. V. Human transforming growth factor-β complementary DNA sequence and expression in normal and transformed cells. Nature (Lond.), 316: 701-705, 1985.
213. Roberts, A. B., Anzano, M. A., Meyers, C. A., Wideman, J., Blacher, R., Pan, Y.-C. E., Stein, S., Lehrman, S. R., Smith, L. C., Lamb, L. C., and Sporn, M. B. Purification and properties of a type-β transforming growth factor from bovine kidney. Biochemistry, 22: 5692-5698, 1983.
214. Sharpies, K., Plowman, G. D., Rose, T. M., Twardzik, D. R., and Purchio, A. F. Cloning and sequence analysis of simian transforming growth factor cDNA. DNA, 6: 239-244, 1987.
215. Derynck, R., Jarrett, J. A., Chen, E. Y., and Goeddel, D. V. The murine transforming growth factor-β precursor. J. Biol. Chem., 261: 4377–4379, 1986.
216. Kryceve-Martinerie, C., Lawrence, D. A., Crochet, J., Jullien, P., and Vigier, P. Further study of β-TGFs released by virally transformed and non-transformed cells. Int. J. Cancer, 35: 553-558, 1985.
217. Lawrence, D. A., Pircher, R., and Jullien, P. Conversion of a high molecular weight latent β-TGF from chicken embryo fibroblasts into a low molecular weight active β-TGF under acidic conditions. Biochem. Biophys. Res. Commun., 133: 1026-1034, 1985.
218. Pircher, R., Jullien, P., and Lawrence, D. A. β-transforming growth factor is Biophys. stored in human blood platelets as a latent high molecular weight complex. Biochem. Res. Commun., 136: 30-37, 1986.
219. Wakefield, L. M., Smith, D. M., Masui, T., Harris, C. C., and Sporn, M. B. Distribution and modulation of the cellular receptor for transforming growth factor-β. J. Cell Biol., 105: 965-975, 1987.
220. O’Connor-McCourt, M. D., and Wakefield, L. M. Latent transforming growth factor-β in serum: a specific complex with α2-macroglobulin. J. Biol. Chem., 262: 14090-14099, 1987.
221. 2-macroglobulin complex is a latent form of transforming growth factor-β. J. Biol. Chem., 263: 1535-1541, 1988.
222. Coffey, R. J., Jr., Kost, L. J., Lyons, R. M., Moses, H. L., and LaRusso, N. F. Hepatic processing of transforming growth factor β in the rat. Uptake, metabolism, and biliary excretion. J. Clin. Invest., 80: 750-757, 1987.
223. Cheifetz, S., Weatherbee, J. A., Tsang, M. L.-S., Anderson, J. K., Mole, J. E., Lucas, R., and Massague, J. The transforming growth factor-β system, a complex pattern of cross-reactive ligands and receptors. Cell, 48: 409-415.1987.
224. Cheifetz, S., Like, B., and Massague, J. Cellular distribution of type I and type II receptors for transforming growth factor-β. J. Biol. Chem., 261: 9972-9978, 1986.
225. Cheifetz, S., Andres, J. L., and Massague, J. The TGFβ receptor type is a membrane proteoglycan. Domain structure of the receptor. J. Biol. Chem., 263: 16984-16991, 1988.
226. Segarini, P. R., and Seyedin, S. M. The high molecular weight receptor to transforming growth factor-β contains glycosaminoglycan chains. J. Biol. Chem., 263: 8366-8370, 1988.
227. Boyd, F. T., and Massague, J. Transforming growth factor-β inhibition of epithelial cell proliferation linked to the expression of a 53 kDa membrane receptor. J. Biol. Chem., 264: 2272-2278, 1989.
228. Marquardt, H., Lioubin, M. N., and Ikeda, T. Complete amino acid sequence of human transforming growth factor type β2. J. Biol. Chem., 262: 12127-12131, 1987.
229. Ohta, M., Greenberg, J. S., Anklesaria, P., Bassols, A., and Massague, J. Two forms of transforming growth factor-β distinguished by multipotential haematopoietic progenitor cells. Nature (Lond.), 329: 539-541, 1987.
230. ten Dijke, P., Hansen, P., Iwata, K. K., Pieler, C., and Foulkes, J. G. Identification of another member of the transforming growth factor type β gene family. Proc. Natl. Acad. Sci. USA, 85: 4717-4719, 1988.
231. Derynck, R., Lindquist, P. B., Lee, A., Wen, D., Tamm, J., Graycar, J. L., Rhee, L., Mason, A. J., Miller, D. A., Coffey, R. J., Moses, H. L., and Chen, E. Y. A new type of transforming growth factor, TGF-β3. EMBO J., 7: 3737-3743, 1988.
232. Massague, J. The TGF-β family of growth and differentiation factors. Cell, 49:437-438, 1987.
233. Seyedin, S. M., Segarini, P. R., Rosen, D. M., Thompson, A. Y., Bentz, H., and Graycar, J. Cartilage-inducing factor-β is a unique protein structurally and functionally related to transforming growth factor-β. J. Biol. Chem., 262: 1946-1949, 1987.
234. Florini, J. R., Roberts, A. B., Ewton, D. Z., Falen, S. L., Flanders, K. C., and Sporn, M. B. Transforming growth factor-β: a very potent inhibitor of myoblast differentiation, identical to the differentiation inhibitor secreted by Buffalo rat liver cells. J. Biol. Chem., 261: 16509-16513, 1986.
235. Holley, R. W., Armour, R., and Baldwin, J. H. Density-dependent regulation of growth of BSC-1 cells in cell culture: growth inhibitors formed by the cells. Proc. Natl. Acad. Sci. USA, 75: 1864-1866, 1978.
236. Holley, R. W., Bohlen, P., Fava, R., Baldwin, J. H., Kleeman, G., and Armour, R. Purification of kidney epithelial cell growth inhibitors. Proc. Natl. Acad. Sci. USA, 77: 5989-5992, 1980.
237. Tucker, R. F., Shipley, G. D., Moses, H. L., and Holley, R. W. Growth inhibitor from BSC-1 cells is closely related to the platelet type β transforming growth factor. Science (Wash. DC), 226: 705-707, 1984.
238. Hanks, S. K., Armour, R., Baldwin, J. H., Maldonado, F., Spiess, J., and Holley, R. W. Amino acid sequence of the BSC-1 cell growth inhibitor (polyergin) deduced from the nucleotide sequence of the cDNA. Proc. Natl. Acad. Sci. USA, 85: 79-82, 1988.
239. Wrann, M., Bodmer, S., de Martin, R., Siepl, C., Hofer-Warbinek, R., Frei, K., Hofer, E., and Fontana, A. T-cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-β. EMBO J., 6: 1633-1636, 1987.
240. de Martin, R., Haendler, B., Hofer-Warbinek, R., Gaugitsch, H., Schluse-ner, H., Seifert, J. M., Bodmer, S., Fontana, A., and Hofer, E. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family. EMBO J., 6: 3676-3677, 1987.
241. Mason, A. J., Hayflick, J. S., Ling, N., Esch, F., Ueno, N., Ying, S.-Y., Guillemin, R., Niall, H., and Seeburg, P. H. Complementary DNA sequences of ovarian follicular fluid inhibin show precursor structure and homology with transforming growth factor-β. Nature (Lond.), 318: 659-663,1985.
242. Cate, R. L., Mattaliano, R. J., Hession, C., Tizard, R., Farber, N. M., Cheung, A., Ninfa, E. G., Frey, A. Z., Gash, D. J., Chow, E. B., Fisher, R. A., Bertonis, J. M., Torres, G., Wallner, B. P., Ramachandran, K. L., Ragin, R. C., Manganaro, T. F., MacLaughlin, D. T., and Donahoe, P. K. Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells. Cell, 45: 685-698, 1986.
243. Padgett, R. W. St. Johnston, R. D., and Gelbart, W. M. A transcript from a Drosophila pattern gene predicts a protein homologous to the transforming growth factor-β family. Nature (Lond.), 325: 81-84, 1987.
244. Weeks, D. L., and Melton, D. A. A maternal mRNA localized to the vegetal hemisphere in Xenopus eggs codes for a growth factor related to TGFβ. Cell, 51: 861-867, 1987.
245. Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., and Sporn, M. B. New class of transforming growth factors potentiated by epidermal growth factor: isolation from nonneoplastic tissues. Proc. Natl. Acad. Sci. USA, 78: 5339-5343, 1981.
246. Centrella, M., McCarthy, T. L., and Canalis, E. Transforming growth factorβ is a bifunctional regulator of replication and collagen synthesis in osteoblast-enriched cell cultures from fetal rat bone. J. Biol. Chem., 262: 2869-2874.1987.
247. Robey, P. G., Young, M. F., Flanders, K. C., Roche, N. S., Kondaiah, P., Reddi, A. H., Termine, J. D., Sporn, M. B., and Roberts, A. B. Osteoblasts synthesize and respond to transforming growth factor-type β (TGFβ) in vitro. J. Cell Biol., 105: 457-463, 1987.
248. Shipley, G. D., Tucker, R. F., and Moses, H. L. Type β-transforming growth factor/growth inhibitor stimulates entry of monolayer cultures of AKR-2B cells into S phase after a prolonged prereplicative interval. Proc. Natl. Acad. Sci. USA, 82: 4147-4151, 1985.
249. Leof, E. B., Proper, J. A., Goustin, A. S., Shipley, G. D., DiCorleto, P. E., and Moses, H. L. Induction of c-sis mRNA and activity similar to platelet-derived growth factor by transforming growth factor-β: a proposed model for indirect mitogenesis involving autocrine activity. Proc. Natl. Acad. Sci. USA, 83: 2453-2457, 1986.
250. Pertovaara, L., Sistonen, L., Bos, T. J., Vogt, P. K., Keski-Oja, J., and Alitalo, K. Enhanced jun gene expression is an early genomic response to transforming growth factor-β. Mol. Cell. Biol., 9:1255-1262, 1989.
251. Keski-Oja, J., Postlethwaite, A. E., and Moses, H. L. Transforming growth factors in the regulation of malignant cell growth and invasion. Cancer Invest., 6: 37-56, 1988.
252. Moses, H. L., Tucker, R. F., Leof, E. B., Coffey, R. J. J., Halper, J., and Shipley, G. D. Type β transforming growth factor is a growth stimulator and a growth inhibitor. In: J. Feramisco, B. Ozanne, and C. Stiles (eds.), Cancer Cells, Vol. 3, pp. 65–75. Cold Spring Harbor, NY: Cold Spring Harbor Press, 1985.
253. Roberts, A. B., Anzano, M. A., Wakefield, L. M., Roche, N. S., Stern, D. F., and Sporn, M. B. Type-β transforming growth factor: a bifunctional regulator of cellular growth. Proc. Natl. Acad. Sci. USA, 82: 119-123, 1985.
254. Masui, T., Wakefield, L. M., Lechner, J. F., LaVeck, M. A., Sporn, M. B., and Harris, C. C. Type β transforming growth factor is the primary differentiation-inducing serum factor for normal human bronchial epithelial cells. Proc. Natl. Acad. Sci. USA, 83: 2438-2442, 1986.
255. Massague, J., Cheifetz, S., Endo, T., and Nadal-Ginard, B. Type β transforming growth factor is an inhibitor of myogenic differentiation. Proc. Natl. Acad. Sci. USA, 83: 8206-8210, 1986.
256. Ignotz, R. A., and Massague, J. Type β transforming growth factor controls the adipogenic differentiation of 3T3 fibroblasts. Proc. Natl. Acad. Sci. USA, 82: 8530-8534, 1985.
257. Josso, N., Picard, J.-Y., and Tran, D. The antimullerian hormone. Recent Prog. Horm. Res., 33: 117-158, 1977.
258. Kimelman, D., and Kirschner, M. Synergistic induction of mesoderm by FGF and TGFβ and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell, 51: 869-877, 1987.
259. Rosa, F., Roberts, A. B., Danielpour, D., Dart, L. L., Sporn, M. B., and Dawid, I. B. Mesoderm induction in amphibians: the role of TGFβ2-like factors. Science (Wash. DC), 239: 783-785, 1988.
260. Sporn, M. B., Roberts, A. B., Shull, J. H., Smith, J. M., Ward, J. M., and Sodek, J. Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo. Science (Wash. DC), 219: 1329-1331, 1983.
261. Roberts, A. B., Sporn, M. B., Assoian, R. K., Smith, J. M., Roche, N. S., Wakefield, L. M., Heine, U. I., Liotta, L. A., Falanga, V., Kehrl, J. H., and Fauci, A. S. Transforming growth factor type-β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc. Natl. Acad. Sci. USA, 83: 4167-4171, 1986.
262. Mustoe, T. A., Pierce, G. F., Thomason, A., Gramates, P., Sporn, M. B., and Deuel, T. F. Accelerated healing of incisional wounds in rats induced by transforming growth factor-β. Science (Wash. DC), 237: 1333–1336, 1987.
263. Ellingsworth, L. R., Brennan, J. E., Fok, K., Rosen, D. M., Bentz, H., Piez, K. A., and Seyedin, S. M. Antibodies to the N-terminal portion of cartilage-inducing factor A and transforming growth factor β. Immunohistochemical localization and association with differentiating cells. J. Biol. Chem., 261: 12362-12367, 1986.
264. Tashjian, A. H. J., Voelkel, E. F., Lazzaro, M., Singer, F. R., Roberts, A. B., Derynck, R., Winkler, M. E., and Levine, L. α and β human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse calvaria. Proc. Natl. Acad. Sci. USA, 82: 4535-4538, 1985.
265. Ignotz, R. A., and Massague, J. Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem., 261: 4337-4345, 1986.
266. Ignotz, R. A., Endo, T., and Massague, J. Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-β. J. Biol. Chem., 262: 6443-6446, 1987.
267. Raghow, R., Postlethwaite, A. E., Keski-Oja, J., Moses, H. L., and Kang, H. Transforming growth factor-β increases steady-state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J. Clin. Invest., 79: 1285-1288, 1987.
268. Keski-Oja, J., Raghow, R., Sawdey, M., Loskutoff, D. J., Postlethwaite, A. E., Kang, A. H., and Moses, H. L. Regulation of mRNAs for type-1 plasminogen activator inhibitor, fibronectin, and type-1 procollagen by transforming growth factor-β: divergent responses in lung fibroblasts and carcinoma cells. J. Biol. Chem., 263: 3111-3115, 1988.
269. Pearson, C. A., Pearson, D., Shibahara, S., Hofsteenge, J., and Chiquet-Ehrismann, R. Tenascin: cDNA cloning and induction by TGFβ. EMBO J., 7: 2677–2681, 1988.
270. Fine, A., and Goldstein, R. H. The effect of transforming growth factor-β on cell proliferation and collagen formation by lung fibroblasts. J. Biol. Chem., 262: 3897-3902, 1987.
271. Bassols, A., and Massague, J. Transforming growth factor β regulates the expression and structure of extracellular matrix chondroitin/dermatan sulfate proteoglycans. J. Biol. Chem., 263: 3039-3045, 1988.
272. Penttinen, R. P., Kobayashi, S., and Bornstein, P. Transforming growth factor β increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc. Natl. Acad. Sci. USA, 85: 1105-1108,1988.
273. Ignotz, R. A., and Massague, J. Cell adhesion protein receptors as targets for transforming growth factor-β action. Cell, 51: 189-197,1987.
274. Heino, J., Ignotz, R. A., Hemler, M. E., Crouse, C., and Massague, J. Regulation of cell adhesion receptors by transforming growth factor-β. J. Biol. Chem., 264: 380-388, 1989.
275. Hynes, R. O. Integrins: a family of cell surface receptors. Cell, 48: 549–554, 1987.
276. Saksela, O., Laiho, M., and Keski-Oja, J. Regulation of plasminogen activator activity in human fibroblastic cells by fibrosarcoma cell-derived factors. Cancer Res., 45: 2314-2319, 1985.
277. Laiho, M. Modulation of extracellular proteolytic activity and anchorage-independent growth of cultured cells by sarcoma cell-derived factors. Relationships to transforming growth factor-β. Exp. Cell Res., 176: 297–308, 1988.
278. Laiho, M., Saksela, O., and Keski-Oja, J. Transforming growth factor-β alters plasminogen activator activity in human skin fibroblasts. Exp. Cell Res., 164: 399-407, 1986.
279. Keski-Oja, J., Blasi, F., Leof, E. B., and Moses, H. L. Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-β. J. Cell Biol., 106: 451-459,1988.
280. 35S]methionine into proteins secreted by African green monkey (BSC-1) cells. Proc. Natl. Acad. Sci. USA, 80: 5636-5640, 1983.
281. Thalacker, F. W., and Nilsen-Hamilton, M. Specific induction of secreted proteins by transforming growth factor-β and 12-O-tetradecanoylphorbol-13-acetate. J. Biol. Chem., 262: 2283-2290, 1987.
282. Chiang, C.-P., and Nilsen-Hamilton, M. Opposite and selective effects of epidermal growth factor and human platelet transforming growth factor-β on the production of secreted proteins by murine 3T3 cells and human fibroblasts. J. Biol. Chem., 261: 10478-10481, 1986.
283. Rheinwald, J. G., Jorgensen, J. L., Hahn, W. C., Terpstra, A. J., O’Connell, T. M., and Plummer, K. K. Mesosecrin: a secreted glycoprotein produced in abundance by human mesothelial, endothelial, and kidney epithelial cells in culture. J. Cell Biol., 104: 263-275, 1987.
284. Lund, L. R., Riccio, A., Andreasen, P. A., Nielsen, L. S., Kristensen, P., Laiho, M., Saksela, O., Blasi, F., and Dano, K. Transforming growth factor-β is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J., 6: 1281-1286, 1987.
285. Andreasen, P. A., Pyke, C., Riccio, A., Kristensen, P., Nielsen, L. S., Lund, L. R., Blasi, F., and Dano, K. Plasminogen activator inhibitor type 1 biosynthesis and human mRNA level are increased by dexamethasone in human fibrosarcoma cells. Mol. Cell. Biol., 7: 3021-3025,1987.
286. Riccio, A., Lund, L. R., Sartorio, R., Lania, A., Andreasen, P. A., Dano, K., and Blasi, F. The regulatory region of the human plasminogen activator inhibitor type-1 (PA1-1) gene. Nucl. Acids Res., 16: 2805-2824, 1988.
287. Rossi, P., Karsenty, G., Roberts, A. B., Roche, N. S., Sporn, M. B., and de Crombrugghe, B. A nuclear factor 1 binding site mediates the transcriptional activation of a type I collagen promoter by transforming growth factor-β. Cell, 52: 405-414, 1988.
288. Davies, R. L., Rifkin, D. B., Tepper, R., Miller, A., and Kucherlapati, R. A polypeptide secreted by transformed cells that modulates human plasminogen activator production. Science (Wash. DC), 221: 171-173, 1983.
289. Hedman, K., Kurkinen, M., Alitalo, K., Vaheri, A., Johansson, S., and Hook, M. Isolation of the pericellular matrix of human fibroblast cultures. J. Cell Biol., 81: 83-91, 1979.
290. Kleinman, H. K., Klebe, R. J., and Martin, G. R. Role of collagenous matrices in the adhesion and growth of cells. J. Cell Biol., 88: 473–485, 1981.
291. Alitalo, K., and Vaheri, A. Pericellular matrix and malignant transformation. Adv. Cancer Res., 37: 111–158, 1982.
292. Liotta, L. A. Tumor invasion and metastases-role of the extracellular matrix. Cancer Res., 46: 1-7, 1986.
293. Quigley, J. P. Association of a protease (plasminogen activator) with a specific membrane fraction isolated from transformed cells. J. Cell Biol., 71: 472-486, 1976.
294. Chen, W.-T., Olden, K., Bernard, B. A., and Chu, F.-F. Expression of transformation-associated protease(s) that degrade fibronectin at cell contact sites. J. Cell Biol., 98: 1546-1555, 1984.
295. Tryggvason, K., Hoyhtya, M., and Salo, T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim. Biophys. Acta, 907: 191-217,1987.
296. Chen, J.-M., and Chen, W.-T. Fibronectin-degrading proteases from the membranes of transformed cells. Cell, 48: 193-203, 1987.
297. Werb, Z., Mainardi, C. L., Vater, C. A., and Harris, E. D. Endogenous activation of latent collagenase by rheumatoid synovial cells. N. Engl. J. Med., 296: 1017-1023, 1977.
298. O’Grady, R. L., Upfold, L. I., and Stephens, R. W. Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator. Int. J. Cancer, 28: 509-515, 1981.
299. Salo, T., Liotta, L. A., Keski-Oja, J., Turpeenniemi-Hujanen, T., and Tryggvason, K. Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells-role in metastasis. Int. J. Cancer, 30: 669-673, 1982.
300. Mimuro, J., Schleef, R. R., and Loskutoff, D. J. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood, 70: 721-728, 1987.
301. Knudsen, B. S., Harpel, P. C., and Nachman, R. L. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J. Clin. Invest., 80: 1082-1089, 1987.
302. Levin, E. G., and Santell, L. Association of a plasminogen activator inhibitor (PAI-1)with the growth substratum and membrane of human endothelial cells. J. Cell Biol., 105: 2543-2549, 1987.
303. Sakata, Y., Okada, M., Noro, A., and Matsuda, M. Interaction of tissue-type plasminogen activator and plasminogen activator inhibitor 1 on the surface of endothelial cells. J. Biol. Chem., 263: 1960-1969, 1988.
304. Keski-Oja, J., and Todaro, G. J. Specific effects of fibronectin-releasing peptides on the extracellular matrices of cultured human fibroblasts. Cancer Res., 40: 4722-4727, 1980.
305. Keski-Oja, J., and Vaheri, A. The cellular target for the plasminogen activator, urokinase, in human fibroblasts—66.000 dalton protein. Biochim. Biophys. Acta, 720: 141-146, 1982.
306. Quigley, J. P., Gold, L. I., Schwimmer, R., and Sullivan, L. Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells. Proc. Natl. Acad. Sci. USA, 84: 2776-2780, 1987.
307. Heisel, M., Laug, W. E., and Jones, P. A. Inhibition by bovine endothelial cells of degradation by HT-1080 fibrosarcoma cells of extracellular matrix proteins. J. Natl. Cancer Inst., 71: 1183-1187, 1983.
308. Hebert, C. A., and Baker, J. B. Linkage of extracellular plasminogen activator to the fibroblast cytoskeleton: colocalization of cell surface urokinase with vinculin. J. Cell Biol., 106: 1241-1247, 1988.
309. Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., and Shafie, S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (Lond.), 284: 67-68, 1980.
310. Mignatti, P., Robbins, E., and Rifkin, D. B. Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade. Cell, 47: 487-498,1986.
311. Matrisian, L. M., Glaichenhaus, N., Gesnel, M.-C., and Breathnach, R. Epidermal growth factor and oncogenes induce transcription of the same cellular mRNA in rat fibroblasts. EMBO J., 4: 1435-1440, 1985.
312. Matrisian, L. M., Leroy, P., Ruhlmann, C., Gesnel, M.-C., and Breathnach, R. Isolation of the oncogene and epidermal growth factor-induced transin gene: complex control in rat fibroblasts. Mol. Cell. Biol., 6: 1679–1686, 1986.
313. Edwards, D. R., Murphy, G., Reynolds, J. J., Whitham, S. E., Docherty, A. J. P., Angel, P., and Heath, J. K. Transforming growth factor-β modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J., 6: 1899-1904,1987.
314. Whitham, S. E., Murphy, G., Angel, P., Rahmsdorf, H.-J., Smith, B. J., Lyons, A., Harris, T. J. R., Reynolds, J. J., Herrlich, P., and Docherty, A. J. P. Comparison of human stromelysin and collagenase by cloning and sequence analysis. Biochem. J., 240: 913-916, 1986.
315. Machida, C. M., Muldoon, L. L., Rodland, K. D., and Magun, B. E. Transcriptional modulation of transin gene expression by epidermal growth factor and transforming growth factor beta. Mol. Cell. Biol., 8: 2479-2483, 1988.
316. Chua, C. C., Geiman, D. E., Keller, G. H., and Ladda, R. L. Induction of collagenase secretion in human fibroblast cultures by growth promoting factors. J. Biol. Chem., 260: 5213-5216, 1985.
317. Gottesman, M. M. Transformation-dependent secretion of a low molecular weight protein by murine fibroblasts. Proc. Natl. Acad. Sci. USA, 75: 2767-2771, 1978.
318. Denhardt, D. T., Hamilton, R. T., Parfett, C. L. J., Edwards, D. R. St., Pierre, R., Waterhouse, P., and Nilsen-Hamilton, M. Close relationship of the major excreted protein of transformed murine fibroblasts to thiol-dependent cathepsins. Cancer Res., 46: 4590-4593, 1986.
319. Overall, C. M., Wrana, J. L., and Sodek, J. Independent regulation of collagenase, 72-kDA progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor β. J. Biol. Chem. 264: 1860-1869, 1989.
320. Vlodavsky, I., Folkman, J., Sullivan, R., Fridman, R., Ishai-Michael, R., Sasse, J., and Klagsbrun, M. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc. Natl. Acad. Sci. USA, 84: 2292-2296, 1987.
321. Baird, A., and Ling, N. Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: implications for a role of heparinase-like enzymes in the neovascular response. Biochem. Biophys. Res. Commun., 142: 428-435, 1987.
322. Saksela, O., Moscatelli, D., Sommer, A., and Rifkin, D. B. Endothelial cell-derived heparan sulfate binds basic fibroblast and protects it from proteolytic degradation. J. Cell Biol., 107: 743-751, 1988.
323. Rosengart, T. K., Johnson, W. V., Friesel, R., Clark, R., and Maciag, T. Heparin protects heparin-binding growth factor-I from proteolytic inactivation in vitro. Biochem. Biophys. Res. Commun., 152: 432-440, 1988.
324. Postlethwaite, A. E., Keski-Oja, J., Moses, H. L., and Kang, A. H. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor β. J. Exp. Med., 165: 251-256, 1987.
325. Wahl, S. H., Hunt, D. A., Wakefield, L. M., McCartney-Francis, N., Wahl, L. M., Roberts, A. B., and Sporn, M. B. Transforming growth factor type β induces monocyte chemotaxis and growth factor production. Proc. Natl. Acad. Sci. USA, 84: 5788-5792, 1987.
326. Van Obberghen-Schilling, E., Roche, N. S., Flanders, K. C., Sporn, M. B., and Roberts, A. B. Transforming growth factor β1 positively regulates its own expression in normal and transformed cells. J. Biol. Chem., 263: 7741-7746, 1988.
327. Baird, A., and Durkin, T. Inhibition of endothelial cell proliferation by type β-transforming growth factor: interactions with acidic and basic fibroblast growth factors. Biochem. Biophys. Res. Commun., 138: 476-482, 1986.
328. Frater-Schroder, M., Muller, G., Birchmeier, W., and Bohlen, P. Transforming growth factor-β inhibits endothelial cell proliferation. Biochem. Biophys. Res. Commun., 137: 295-302, 1986.
329. Heimark, R. L., Twardzik, D. R., and Schwartz, S. M. Inhibition of endothelial regeneration by type-β transforming growth factor from platelets. Science (Wash. DC), 233: 1078-1080, 1986.
330. Takehara, K., LeRoy, E. C., and Grotendorst, G. R. TGFβ-induction of endothelial cell proliferation: alteration of EGF binding and EGF-induced growth-regulatory (competence) gene expression. Cell, 49: 415-422, 1987.
331. Muller, G., Behrens, J., Nussbaumer, U., Bohlen, P., and Birchmeier, W. Inhibitory action of transforming growth factor β on endothelial cells. Proc. Natl. Acad. Sci. USA, 84: 5600-5604, 1987.
332. McCartney-Francis, N., Mizel, D., Wongh, H., Wahl, L., and Wahl, S. Transforming growth factor-β as an immunoregulatory molecule. FASEB J., 2: A875, 1988.
333. Miyazono, K., Heilman, U., Wernstedt, C., and Heldin, C.-H. Latent high molecular weight complex of transforming growth factor 01. Purification from human platelets and structural characterization. J. Biol. Chem., 263: 6407-6415, 1988.
334. Gentry, L. E., Webb, N. R., Lim, G. J., Brunner, A. M., Ranchalis, J. E., Twardzik, D. R., Lioubin, M. N., Marquardt, H., and Purchio, A. F. Type 1 transforming growth factor-β: amplified expression and secretion of mature and precursor polypeptide in Chinese hamster ovary cells. Mol. Cell. Biol., 7: 4318-4327, 1987.
335. Clemmons, D. R., Han, V. K. M., Elgin, R. G., and D’Ercole, A. J. Alterations in the synthesis of a fibroblast surface associated 35 Kd protein modulates the binding of somatomedin-C/insulin-like growth factor I. Mol. Endocrinol., 1: 339-347, 1987.
336. Elgin, R. G., Busby, W. H., Jr., and Clemmons, D. R. An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I. Proc. Natl. Acad. Sci. USA, 84: 3254-3258, 1987.
337. Mignotti, P., Tsubai, R. Robbins, E., and Rifkin, D. B. In vitro angiogenesis of the human amniotic membrane: requirement for basic fibroblast growth factor-induced proteinases. J. Cell. Biol., 108: 671-682, 1989.